Table 10. Aripiprazole on QT interval in adults with mental disorders.
| Outcome | Risk with intervention per 1,000 | Risk with comparator per 1,000 | Relative measure of association | Number of participants (studies) | Quality (GRADE) | Comments† |
|---|---|---|---|---|---|---|
| Aripiprazole versus placebo | ||||||
| Prolongation of QT interval during the study | 0 | 0 | RR undetermined | 135 (1 RCT) (90) | Very low | No difference |
| Prolongation of QT interval >30 msec | 43 | 56 | RR 0.78 (0.47, 1.28) | 1,339 (5 RCTs) (89) | Low | No difference |
| Prolongation of QTc interval >450 msec | 2 | 2 | RR 0.89 (0.08, 9.81) | 1,339 (5 RCTs) (89) | Low | No difference |
| QTc Bazett >450 msec | 142 | 58 | RR 2.43 (0.28, 21.29) | 38 (1 RCT) (94) | Very low | No difference |
| QTc Bazett Change from Baseline >30 msec | 238 | 176 | RR 1.35 (0.37, 4.86) | 38 (1 RCT) (94) | Very low | No difference |
| QTc Bazett Change from Baseline >60 msec | 0 | 58 | RR 0.27 (0.01, 6.25) | 39 (1 RCT) (94) | Very low | No difference |
| QTcF >450 msec | 47 | 58 | RR 0.81 (0.05, 12.01) | 38 (1 RCT) (94) | Very low | No difference |
| QTcF change from baseline >30 msec | 142 | 235 | RR 0.61 (0.16, 2.35) | 38 (1 RCT) (94) | Very low | No difference |
| QTcF change from baseline >60 msec | 0 | 58 | RR 0.27 (0.01, 6.25) | 39 (1 RCT) (94) | Very low | No difference |
| 200 versus 300 mg aripiprazole IM Depot | ||||||
| Electrocardiogram QT corrected interval prolonged | 100 | 133 | RR 0.75 (0.08, 7.21) | 25 (1 RCT) (96) | Very low | No difference |
| 200 versus 400 mg aripiprazole IM Depot | ||||||
| Electrocardiogram QT corrected interval prolonged | 100 | 0 | RR 4.20 (0.19, 92.87) | 24 (1 RCT) (96) | Very low | No difference |
| 300 versus 400 mg aripiprazole IM Depot | ||||||
| Electrocardiogram QT corrected interval prolonged | 133 | 0 | RR 4.67 (0.24, 88.96) | 29 (1 RCT) (96) | Very low | No difference |
| Aripiprazole versus risperidone | ||||||
| Prolongation of QT interval | 0 | 30 | RR 0.07 (0.00, 1.36) | 300 (1 RCT) (91) | Very low | No difference |
| Aripiprazole versus haloperidol | ||||||
| Prolongation of QT interval | 0 | 0 | RR undetermined | 424 (1 RCT) (92) | Very low | No difference |
| Prolongation of QT interval >30 msec | 43 | 80 | RR 0.54 (0.31, 0.94) | 1,126 (5 RCTs) (89) | Low | No difference |
†, we concluded that there is no difference in outcomes between active and control interventions based on P value >0.05 and inability to reject null hypotheses but without post-hoc analysis of the statistical power to detect true differences. 95% confidence interval in (); GRADE, Grading of Recommendations Assessment, Development and Evaluation; RCT, randomized controlled trial; RR, relative risk; MD, mean difference; SMD, standardized mean difference between intervention and comparator where the magnitude of the effect is defined as small (SMD, 0–0.5 standard deviations), moderate (SMD, 0.5–0.8 standard deviations), and large (SMD >0.8 standard deviations); QTc, corrected QT interval; QTcF, Fridericia’s corrected QT interval; NR, not reported.